Established in 2021, it is a professional equity investment management institution specializing in the fields of biomedicine, medical devices, and big health, with a fund management scale of 20 billion yuan. Tailong Investment has a professional and experienced investment team, focusing on biopharmaceuticals, innovative medical devices, CXO core services and innovative fields, and excellent biopharmaceutical industry funds. We are committed to building a biopharmaceutical industry value investment platform that is loyal to science and cross cycle.

Lula Capital was established in 2016, headquartered in Hangzhou, and currently manages a total scale of over 1.5 billion yuan. Lula Capital focuses on venture capital in the pharmaceutical and health industry, with a particular emphasis on fields such as biomedicine, cell therapy, immunotherapy, medical services, digital therapies, and innovative medical devices. The company has an excellent investment management team and consulting team, with a profound understanding of the healthcare industry. The team adheres to the concept of resource sharing, maintains close contact with the management teams and experts of invested enterprises, and shares industry and industrial resources.

Yantai Guofeng Investment Holding Group Co., Ltd. was established in February 2009 and is a wholly state-owned company. The registered capital of the group is 10 billion yuan, with total assets of approximately 330 billion yuan and net assets of approximately 118 billion yuan. It has obtained a double AAA domestic entity credit rating and a Fitch BBB+international entity rating. With the goal of promoting a virtuous cycle of state-owned capital and serving the development of the industrial economy, focusing on the four functions of financing, investment attraction, construction, and service, we strive to promote the sustained and healthy development of six major business sectors including equity management, and fully serve and guarantee the implementation and landing of major investment projects at the municipal level.

Yingke Capital is a research-oriented investment institution that explores industry depth, managing assets worth billions of yuan, with the vast majority of entrusted funds coming from top institutional investors. Adhering to the principle of "discovering the power of economic progress", Yingke Capital's investment field focuses on industries such as "life sciences, dual carbon technology, and hard core technology", and has invested in more than 300 high-quality enterprises, building a highly collaborative industrial ecosystem.

Chenyuan Venture Capital was established in 2021 and is headquartered in Beijing. It is a management institution for venture capital funds focused on the life technology industry. The core team of Chenyuan Venture Capital is composed of several senior professionals in the medical and pharmaceutical industry investment and industry background, as well as multiple industry experts serving as in-depth consultants and support. Having professional knowledge reserves and profound industry accumulation, with an international perspective, as well as connections and resources in the medical industry in both China and the United States.

Boquan Capital (Shanghai Boquan Equity Investment Management Co., Ltd.) was established in Shanghai and is a private equity investment fund manager registered with the China Securities Investment Fund Industry Association.

Boquan Capital adheres to the concept of long-term value investment and focuses on investing in the medical and health fields. It is committed to finding and supporting potential early-stage and growth stage enterprises, transforming accumulated resources into empowerment for enterprises, and growing together with enterprises. Its investment scope covers biopharmaceuticals, medical devices, medical services, and diagnostics.